Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action

References

• Neurath MF, Finotto S. The many roads to inflammatory bowel diseases. Immunity. 2006; 25(2)189–91
   PubMedGoogle Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(7)390–407
   PubMedGoogle Scholar
• Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117(3)514–21
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008; 43(1)1–17
   PubMedGoogle Scholar
• Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut. 1992; 33(7)933–7
   PubMedGoogle Scholar
• Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993; 94(1)174–81
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion. 1991; 50(2)104–11
   PubMedGoogle Scholar
• Mitsuyama K, Toyonaga A, Sasaki E, Watanabe K, Tateishi H, Nishiyama T, et al. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1994; 96(3)432–6
   PubMedGoogle Scholar
• Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol. 2007; 42(10)787–98
   PubMed Web of Science ®Google Scholar
• Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?. Dig Dis Sci. 2007; 52(9)2015–21
   PubMed Web of Science ®Google Scholar
• Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol. 1995; 10(4)387–95
   PubMedGoogle Scholar
• Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994; 35(5)669–74
   PubMedGoogle Scholar
• Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders?. Nat Clin Pract Gastroenterol Hepatol. 2005; 2(5)200–1
   PubMedGoogle Scholar
• Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther. 2006; 6(5)453–66
   PubMed Web of Science ®Google Scholar
• Dzik S. Leukodepletion blood filters: filter design and mechanisms of leukocyte removal. Transfus Med Rev. 1993; 7(2)65–77
   PubMedGoogle Scholar
• Shirokaze J. Leukocytapheresis using a leukocyte removal filter. Ther Apher. 2002; 6(4)261–6
   PubMedGoogle Scholar
• Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther Apher Dial. 2003; 7(1)44–7
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, et al. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher. 1997; 1(3)207–11
   PubMedGoogle Scholar
• Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des. 2003; 9(4)307–21
   PubMedGoogle Scholar
• Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005; 100(6)1362–9
   PubMed Web of Science ®Google Scholar
• Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, et al. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol. 2005; 20(10)1567–71
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995; 30(3)322–9
   PubMedGoogle Scholar
• Sawada K, Ohnishi K, Kosaka T, Fukui S, Yamamura M, Amano K, et al. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol. 1995; 30 Suppl 8: 124–7
   PubMedGoogle Scholar
• Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T. Leukocytapheresis therapy for severe ulcerative colitis. Ther Apher. 1998; 2(2)101–4
   PubMedGoogle Scholar
• Yajima T, Takaishi H, Kanai T, Iwao Y, Watanabe M, Ishii H, et al. Predictive factors of response to leukocytapheresis therapy for ulcerative colitis. Ther Apher. 1998; 2(2)115–9
   PubMedGoogle Scholar
• Honma T, Sugimura K, Asakura H, Matsuzawa J, Suzuki K, Kobayashi M, et al. Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis. J Clin Gastroenterol. 2005; 39(10)886–90
   PubMedGoogle Scholar
• Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci. 2005; 50(4)767–73
   PubMedGoogle Scholar
• Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, et al. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis. 2007; 39(5)422–9
   PubMedGoogle Scholar
• Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis: results of a randomized pilot trial. Dig Dis Sci. 2007; 52(9)2044–53
   PubMedGoogle Scholar
• Araki Y, Mitsuyama K, Nagae T, Tou Y, Nakagawa M, Iwatani Y, et al. Leukocytapheresis for the treatment of active pouchitis: a pilot study. J Gastroenterol. 2008; 43(7)571–5
   PubMedGoogle Scholar
• Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004; 151(5)1090–2
   PubMedGoogle Scholar
• Fukunaga K, Sawada K, Fukuda Y, Matoba Y, Onishi K, Fukui S, et al. A case report: first case of filtration leukocytapheresis for a patient of aortitis syndrome associated with ulcerative colitis. Ther Apher. 2002; 6(1)93–8
   PubMedGoogle Scholar
• Kosaka T, Sawada K, Ohnishi K, Egashira A, Yamamura M, Tanida N, et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med. 1999; 38(2)102–11
   PubMedGoogle Scholar
• Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12 Suppl 1:S15–21.
   Web of Science ®Google Scholar
• Nagase K, Sawada K, Ohnishi K, Egashira A, Ohkusu K, Shimoyama T. Complications of leukocytapheresis. Ther Apher. 1998; 2(2)120–4
   PubMedGoogle Scholar
• Mitsuyama K, Andoh A, Masuda J, Yamasaki H, Kuwaki K, Takedatsu H, et al. Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis. Ther Apher Dial. 2008; 12(4)271–7
   PubMedGoogle Scholar
• D'Odorico A, D'Inca R, Mestriner C, Di Leo V, Ferronato A, Sturniolo GC. Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease. Dig Dis Sci. 2000; 45(8)1594–600
   PubMedGoogle Scholar
• Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, et al. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol. 2005; 11(20)3085–90
   PubMedGoogle Scholar
• Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003; 52(10)1435–41
   PubMedGoogle Scholar
• Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004; 99(5)938–45
   PubMed Web of Science ®Google Scholar
• Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, et al. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol. 2001; 36(12)1301–6
   PubMedGoogle Scholar
• Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, et al. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol. 2006; 41(6)524–32
   PubMedGoogle Scholar
• Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, et al. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol. 2006; 41(6)540–6
   PubMedGoogle Scholar
• Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol. 2005; 100(9)2042–8
   PubMedGoogle Scholar
• Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher. 1998; 2(2)109–14
   PubMedGoogle Scholar
• Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Sasaki M, Obata H, et al. Leukocytapheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Ther Apher Dial. 2005; 9(3)270–6
   PubMedGoogle Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745–63
   PubMed Web of Science ®Google Scholar
• Kanai T, Makita S, Kawamura T, Nemoto Y, Kubota D, Nagayama K, et al. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis. 2007; 13(3)284–90
   PubMedGoogle Scholar
• Emmirich J, Peter B, Sparmann G, Liebe S, Klingel R, Ramlow W. Mobilization of mucosa lymphocytes by leukocytapheresis. Gastroenterology. 2006;130:A661.
   Google Scholar
• Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu H, et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol. 2005; 141(1)130–40
   PubMedGoogle Scholar
• Andoh A, Ogawa A, Kitamura K, Inatomi O, Fujino S, Tsujikawa T, et al. Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol. 2004; 39(12)1150–7
   PubMedGoogle Scholar
• Yagi Y, Andoh A, Ogawa A, Bamba S, Tsujikawa T, Sasaki M, et al. Microarray analysis of leukocytapheresis-induced changes in gene expression patterns of peripheral blood mononuclear cells in patients with ulcerative colitis. Ther Apher Dial. 2007; 11(5)331–6
   PubMedGoogle Scholar
• Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002; 360(9344)1478–80
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood. 2003; 101(5)2064–6
   PubMed Web of Science ®Google Scholar
• Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, et al. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med. 2002; 8(9)1011–7
   PubMedGoogle Scholar
• Brittan M, Hunt T, Jeffery R, Poulsom R, Forbes SJ, Hodivala-Dilke K, et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut. 2002; 50(6)752–7
   PubMed Web of Science ®Google Scholar
• Suemitsu J, Yoshida M, Yamawaki N, Yamashita Y. Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter. Ther Apher. 1998; 2(1)31–6
   PubMedGoogle Scholar
• Sands BE, Sandborn WJ, Feagan B, Lofberg R, Hibi T, Wang T, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008; 135(2)400–9
   PubMed Web of Science ®Google Scholar